Fig. 7: Co-targeting treatment reshapes the PDAC tumor microenvironment.
a Normalized fold change of each cell type in Gem- or Gem+PPIX+Cel-treated KPC mT3 PDACs compared to vehicle-treated KPC mT3 tumors. Statistically significant changes based on Fisher exact test P values are indicated. b Frequencies of total fibroblasts and each fibroblast (sub)cluster in Vehicle-, Gem-, or Gem+PPIX+Cel-treated KPC mT3 tumor samples. c IHC staining of podoplanin in KPC mT3 PDACs with the indicated treatments (meanβΒ±βSD, t-test, nβ=β5β6 biological repeats, scale bar: 50βΒ΅m). d UMAP visualization of the 7282 macrophage cells from vehicle-treated, Gem-treated, and co-targeting therapy (Gem+PPIX+Cel)-treated KPC mT3 tumor sample. Color coding indicates the major (sub)clusters. e The fractions of each macrophage (sub)cluster in KPC mT3 tumors receiving the indicated treatments. f UMAP visualization of the 1942 neutrophils from vehicle-treated, Gem-treated, and Gem+PPIX+Cel-treated KPC mT3 tumor samples. Color coding indicates the major (sub)clusters. g The fractions of each neutrophil (sub)cluster in KPC mT3 tumor samples receiving the indicated treatments. h UMAP visualization of the 2695βT cells from vehicle-, Gem-, and Gem+PPIX+Cel-treated KPC mT3 tumor samples. Color is coded by major (sub)clusters. i The fractions of each T cell (sub)cluster in KPC mT3 tumor samples receiving the indicated treatments.
